Finance

Lists
4559:TYO
Zeria Pharmaceutical Co Ltd
¥2,068.00
-1.29%
(-27.00) 1D
Nov 20, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4559...
Open
¥2,068
High
¥2,088
Low
¥2,058
Mkt. cap
103.65B
Avg. vol.
132.53K
Volume
91.70K
Dividend
2.42%
Quarterly dividend
¥13
Ex-dividend date
Mar 30, 2027
P/E ratio
8.54
52-wk high
¥2,434
52-wk low
¥1,895
EPS
¥242
Shares outstanding
50.11M
No. of employees
2K
Open
¥2,068
High
¥2,088
Low
¥2,058
Mkt. cap
103.65B
Avg. vol.
132.53K
Volume
91.70K
Dividend
2.42%
Quarterly dividend
¥13
Ex-dividend date
Mar 30, 2027
P/E ratio
8.54
52-wk high
¥2,434
52-wk low
¥1,895
EPS
¥242
Shares outstanding
50.11M
No. of employees
2K
News stories
From web sources and news partners
Profile
Zeria Shinyaku Kōgyō KK is a Japanese drug manufacturer that obtained Tillotts Pharma AG. In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho. In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK. In 1975, it built a new factory in Kumagaya in Saitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988. In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries, It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma. The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries. The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ Financial Group, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance as of March 2023. Wikipedia
About Zeria Pharmaceutical Co Ltd
CEOSachiaki Ibe
Employees1.75K
FoundedDec 22, 1955
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
24.12B
25.08B
21.45B
24.01B
Cost of goods sold
6.38B
6.43B
6.22B
7.06B
Cost of revenue
6.38B
6.43B
6.22B
7.06B
Research and development expenses
-
3.71B
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12.82B
4.85B
13.28B
13.25B
Operating expense
12.82B
14.84B
13.28B
13.25B
Total operating expenses
19.19B
21.27B
19.50B
20.32B
Operating income
4.93B
3.81B
1.95B
3.70B
Other non operating income
-81.04M
305.04M
-47.28M
-68.72M
EBT including unusual items
4.63B
3.92B
1.43B
3.76B
EBT excluding unusual items
4.63B
3.76B
1.43B
3.76B
Income tax expense
795.44M
979.56M
547.57M
668.43M
Effective tax rate
-
25.02%
38.21%
17.79%
Other operating expenses
-
-
-
-
Net income
3.82B
2.90B
866.20M
3.09B
Net profit margin
-
11.56%
4.04%
12.88%
Earnings per share
-
-
-
-
Interest and investment income
136.71M
32.29M
305.03M
33.97M
Interest expense
-123.00M
-138.00M
-132.04M
-147.96M
Net interest expenses
13.71M
-105.71M
172.99M
-113.99M
Depreciation and amortization charges
-
5.78B
-
-
EBITDA
6.81B
5.65B
4.24B
6.01B
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps